Archives for July 16, 2006

← 2006

Sugar and olive oil break free from the kitchen

By  Kirsty Barnes

US scientists have discovered that sugar and olive oil do not just belong in the kitchen - but could potentially be used to develop naturally-derived nanomaterials for drug delivery systems and biological scaffolds.

Torrey Pines stirs the emotions with the HS40

By  Wai Lang Chu

Torey Pines Scientific has announced the launch if its new stirring hot plate, which has been designed for use in the chemical, pharmaceutical, biochemical, and laboratories where reproducible, accurate, hands-off sample preparation is carried out.

Nektar opts for payout to avoid court showdown over PEGylation

By  Gregory Roumeliotis

Biopharmaceutical firm Nektar has agreed to fork out $25m (€20m) to settle a patent lawsuit by the University of Alabama in Huntsville (UAH) concerning the company's PEGylation delivery technology currently used in eight approved biologic drugs in the...

AstraZeneca chooses Werum to keep an eye on packaging

By  Gregory Roumeliotis

AstraZeneca will be using Werum's PAS-X system at its two German production sites to collect operating data from its packaging lines and define and evaluate key performance indicators (KPI), improving equipment performance.

GSK's thirst for adjuvants grows

By  Gregory Roumeliotis

GlaxoSmithKline (GSK) has asked vaccine developing firm Antigenics to supply it with more of its QS-21 adjuvant as its vaccines progress in the pipeline, while at the same the British drug giant is pushing ahead with its own adjuvant, MPL, seeking not...

Neuropharma presents new mechanism of action for AD drug

By  Wai Lang Chu

Neuropharma has developed a new treatment for Alzheimer's Disease, which uses a unique method of attack, incorporating a mechanism of action that targets a little-known enzyme that contributes to the proliferation of the neurodegenerative disease.

Archemix allies with Elan to develop aptamers

By  Wai Lang Chu

Archemix has announced the formation of a strategic alliance with Elan to discover and develop first-in-class aptamer therapeutics to treat autoimmune disease.